LINKÖPING, Sweden, May 13, 2025 – AMRA Medical is pleased to announce the highly-anticipated launch of our next-gen AMRA® BCP Scan service – powered by AMRA® Profiler – here at home in Sweden as well as in Germany, marking the start of the device’s availability in EU markets. The launch comes just over a year after AMRA® Profiler 4’s EU Medical Device Regulation (MDR) certification in November of 2023, which followed its 510(k) clearance by the US Food and Drug Administration (FDA) in late 2021.
AMRA® BCP Scan service provides clinicians with fat distribution measurements, including liver fat, in addition to muscle composition biomarkers that comprise a detailed body composition profile (BCP) to assist in the assessment of health risks. Implemented right at the clinic, the service provides rapid, precise, and standardized body composition measurements, contextualizing insights at the individual patient level with high accuracy. The biomarkers underlying the technology have been heavily used in metabolic disease research efforts using the AMRA® Researcher service, and AMRA® Profiler 4’s recent launch in Sweden and Germany brings these powerful and unique biomarkers one step closer to patients everywhere.
Currently, the AMRA® BCP Scan service is additionally available through AMRA’s service provision in the UK, US, and Canada – with plans to roll out in more countries following this successful launch in Sweden and Germany. If you or your organization are based in the currently cleared markets and would like to know more about bringing the AMRA® BCP Scan service to your clinic, please contact info@amramedical.com.
Find out how AMRA is changing the health risk assessment landscape in Sweden just days after launch by learning more about our collaboration with Elfcare. By adding AMRA® BCP Scan to their offering, Elfcare now delivers a detailed analysis of metabolic and musculoskeletal health, in addition to full body MRI and detailed blood panels, to detect health issues early. Booking is now open at elf.care/book, with available slots this week.
You can also learn how AMRA is using MRI-based fat distribution and muscle composition measures to advance both research and clinical care by visiting our website, or get in touch with our knowledgeable scientists at info@amramedical.com to learn more about what AMRA can do for your trials, or for your patients.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA’s gold-standard technology delivers multiple fat and muscle biomarkers – derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical care settings by offering support services via our innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at https://amramedical.com/solutions, or connect with our team of experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in fat distribution and muscle composition assessments in disease research and precision medicine.
MEDIA CONTACT INFORMATION
AMRA Medical
Marie Börjesson, VP Brand & Marketing
0046 70 628 1977
marie.borjesson@amramedical.com